3 Firms Rep ProKidney's $2.64B Go-Public SPAC Deal

By Charlie Innis (January 18, 2022, 1:04 PM EST) -- Clinical-stage kidney disease treatment company ProKidney, guided by Davis Polk and Mintz, said Tuesday it will go public through a merger with a Wachtell-led special purpose acquisition vehicle at a $2.64 billion valuation.

The deal will see ProKidney LP bought by Social Capital Suvretta Holdings Corp. III, the SPAC, which will inject the combined company with up to $825 million in gross cash proceeds. About $250 million of the proceeds total will come from the SPAC's trust account, and the other $575 million will draw from a concurrent private investment in public equity, or PIPE deal, with Winston & Strawn advising...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!